Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus
Vir is working to rapidly determine whether its previously identified anti-coronavirus monoclonal antibodies (mAbs) bind and neutralize 2019-nCoV, also referred to as "Wuhan coronavirus".
Biocon witnesses strong revenue growth of 14% to Rs 1,784 Crore in Q3FY20; plan to raise further capital in future
Biocon has witnessed a strong revenue growth of 14% to Rs 1,784 Crore in Q3FY20, led by Biologics, Small Molecules and Research Services businesses.
FDA grants priority review of GSK’s belantamabmafodotin for patients with relapsed or refractory multiple myeloma
US Food and Drug Administration (FDA) granted a priority review for the company's Biologics License Application (BLA) seeking approval of belantamabmafodotin